MPEG1.md
... ...
@@ -2,6 +2,7 @@
2 2
3 3
## Overview
4 4
Mutations in MPEG1 have been described in DLBCL<sup>1</sup> with the overall rate of mutations somewhat variable across studies. MPEG1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. Coding and non-coding MPEG1 mutations are a feature of the MCD genetic subgroup of DLBCL.
5
+
5 6
## History
6 7
```mermaid
7 8
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
MS4A1.md
... ...
@@ -2,6 +2,7 @@
2 2
3 3
## Overview
4 4
MS4A1 encodes the CD20 protein, which is the target of rituximab and other therapeutic monoclonal antibodies. MS4A1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. In relapsed DLBCLs, MS4A1 is sometimes mutated and these mutations have been shown to reduce CD20 expression.<sup>1</sup>
5
+
5 6
## History
6 7
```mermaid
7 8
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
MTOR.md
... ...
@@ -2,6 +2,7 @@
2 2
3 3
## Overview
4 4
Although mutations in MTOR have been reported in DLBCL<sup>1</sup> and some BL, their role in lymphomagenesis has not been thoroughly studied.
5
+
5 6
## History
6 7
```mermaid
7 8
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
NFKBIA.md
... ...
@@ -2,6 +2,7 @@
2 2
3 3
## Overview
4 4
NFKBIA encodes IκBα, an inhibitor of NF-κB, which regulates the NF-κB signaling pathway by preventing the translocation of NF-κB to the nucleus. Mutations in NFKBIA can disrupt this regulation, leading to constitutive activation of NF-κB signaling, which has an important role in a subset of DLBCLs. Mutations and deletions in NFKBIA are observed in DLBCL and are associated with constitutive activation of the NF-κB pathway. These mutations often occur in the ABC subtype and are associated with the **ST2** genetic subgroup of DLBCL.<sup>1</sup>
5
+
5 6
## History
6 7
```mermaid
7 8
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
NFKBIE.md
... ...
@@ -2,6 +2,7 @@
2 2
3 3
## Overview
4 4
NFKBIE encodes IκBε, a negative regulator of NF-κB. Mutations in NFKBIE can disrupt this regulatory function, leading to constitutive activation of NF-κB signaling.<sup>1</sup> Mutations are relatively common in DLBCL and MCL.<sup>2</sup>
5
+
5 6
## History
6 7
7 8
```mermaid
NFKBIZ.md
... ...
@@ -2,6 +2,7 @@
2 2
3 3
## Overview
4 4
The NFKBIZ gene is a significant player in NF-κB signaling, with mutations leading to its deregulation. This pathway is critical in the pathogenesis of ABC DLBCL. NFKBIZ is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. The predominant cluster of mutations in NFKBIZ is in the 3' UTR and not a consequence of aSHM. NFKBIZ 3' UTR mutations confer a selective growth advantage in DLBCL cells by stabilizing NFKBIZ mRNA, resulting in increased protein levels.<sup>1</sup>
5
+
5 6
## History
6 7
```mermaid
7 8
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%